BACKGROUND AND OBJECTIVES. CD56 antigen expression has been reported in several
hematologic malignancies. In acute myeloid leukemia (AML) M2 with t (8; 21) and acute …

The aims of this study were to investigate the frequency and prognostic relevance of CD56
expression in patients with acute myeloid leukemia (AML) and to compare the importance of …

BACKGROUND: The expression of CD56 is considered a bad prognostic factor for overall
survival, lower rates or short complete remission and extramedullary invasion but the results …

Abstract CD56 antigen, a 200–220 kDa cell surface glycoprotein, identified as an isoform of
the neural adhesion molecules (NCAM), has been found frequently expressed in several …

ABSTRACT Objectives Previous study (Br. J. Haematol. 2017; 176: 498) reported that CD56
positive is associated with poor prognosis of patients with intermediate-risk acute myeloid …

CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic
phenotype and resistance to induction therapy but no inferior survival after risk-adapted …

CD56 expression in acute myeloid leukemia (AML) has been associated with
extramedullary leukemia and multidrug resistance, but its clinical and prognostic …

The expression of the pluripotent stem cell antigen CD34 was evaluated at diagnosis in forty-
five adult patients with de now ALL. Comparison of clinical and hematological features …

Background The expression of the CD34 antigen on the blast cells of acute myeloid
leukemia (AML) has been regarded as an unfavorable prognostic factor for the achievement …

Background: The aim of this review was to evaluate the influence of aberrant phenotypes in
prognosis and survival in acute myeloid leukemia (AML) patients by multiparametric flow …